Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor

CAMBRIDGE, UK, NEW YORK, HOUSTON and SOUTH SAN FRANCISCO 06 November, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma. Under the agreement, Artios has exclusive […]

6 November 2019
Read more
Legal Assistant – part time permanent vacancy

Artios Pharma is currently recruiting for a part-time Legal Assistant. This represents an opportunity for an experienced paralegal/legal assistant to join a world class research and development company based south of Cambridge, UK. Artios is a well-funded private biotechnology company focused on identifying and developing medicines to treat cancer that target cellular DNA damage response, […]

10 October 2019
Read more
Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States

Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States. Tania is based at Artios’s new offices […]

24 September 2019
Read more
Scientist /Senior Scientist: Cell and Molecular Biology – Maternity Cover

With an expanding small molecule drug discovery portfolio Artios Pharma is recruiting for an experienced cell and molecular biologist. This is an excellent opportunity to join a world class research team in a dynamic, small Biotech company based south of Cambridge, UK. Artios is focused on identifying and developing cancer treatments by exploiting novel targets […]

23 August 2019
Read more
Laboratory Technician

With an expanding small molecule drug discovery portfolio Artios Pharma is recruiting for a laboratory technician to co-ordinate the day-to-day running of our biochemistry and cell biology labs. This is an excellent opportunity to join a world class research team in a dynamic, small Biotech company based south of Cambridge, UK.  Artios is focused on […]

14 June 2019
Read more
Biotech CEO’s: Can Scientist Founders Remain in Charge?

Artios Pharma CEO Niall Martin was featured in InVivo’s piece on “Biotech CEOs: Entrepreneurs who want to translate their ideas into companies”.

29 May 2019
Read more
‘Putting DNA repair on the map’- Artios CEO interviewed by Labiotech

Artios is on a mission to put DNA repair on the map. Niall Martin talked to Labiotech about his experiences as CEO and explained why it’s important to plan ahead, protect your technology and not to sell out too short or too soon. Putting DNA Repair on the Map    

29 May 2019
Read more
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

Establishes New Clinical Advisory Board of Leading Oncology Experts Cambridge, UK, 1 April 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Ian Smith, M.D., as Chief Medical Officer. Dr. Smith will assume responsibility for leading Artios’s overall […]

1 April 2019
Read more
Upcoming conferences Artios Pharma are attending in 2019

March (14) BioCapital 2019 (organised by LSP) – Artios presenting, Amsterdam, Netherlands (25-27) Bio-Europe Spring, Vienna, Austria (29 – April 3) AACR Annual Meeting, Atlanta, GA USA – – Artios presenting abstract – Graeme Smith, Niall Martin, and Peter Harris attending   April (3-4) 2019 Research and Innovation ELRIG Conference, Cambridge, UK (8-11) 33rd Genes and […]

27 February 2019
Read more
Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

Cambridge, UK, 11 February 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED). In an exceptional career in Pharmaceutical R&D Professor Chopra has held a number of distinguished roles including Corporate […]

11 February 2019
Read more
BioCentury Emerging Company Profile: Artios – Probing DNA Damage

Artios is attacking a different DNA Damage Response pathway that could be more selective than PARP inhibitors.  

30 January 2019
Read more
Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors’ Andrew Scott sits down with Arix Bioscience Plc’s (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma to discuss the Series B financing. https://www.proactiveinvestors.co.uk/companies/stocktube/10188/artios-in-strong-position-to-accelerate-cancer-programmes-after-arix-investment-10188.html  

19 December 2018
Read more
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023. https://scrip.pharmaintelligence.informa.com/SC123568/Artios-Pharma-Hooks-Novartis–Pfizer-In-OverSubscribed-65M-Series-B-Round  

19 December 2018
Read more
Artios Pharma Wins 2018 Lifestars EU Private Finance Raise of the Year Award

Cambridge, UK, 14 November 2018. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, is pleased to announce that it has won the 2018 Lifestars “>£30m EU Private Finance Raise of the Year” Award.

14 November 2018
Read more
Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017. […]

23 October 2018
Read more
Artios Pharma Announces $84 million (£65 million) Series B Financing

Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion of a $84 million (£65 million) Series B financing following high interest from investors.

10 August 2018
Read more
Artios exercises option to in-license potential first-in-class nuclease development programme

Cambridge, UK, 5 March 2018. Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in […]

5 March 2018
Read more
Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

  Industry leader who brings over 35 years of experience in developing successful pharmaceutical companies Cambridge UK, 26 February 2018 – Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Pierre Legault MBA, CA, CPA as Chairman of its Board of Directors, with immediate […]

26 February 2018
Read more
Interview with Artios’ CEO following Biotech and Money’s Awards 2017

Artios Pharma scooped two awards at the Biotech and Money Awards 2017. The DNA Damage Response company was named winner in the UK Life Science Young Company of the Year (1-3 years old) category and the UK Private Finance Raise of the Year (≤£25 million) category. Biotech and Money spoke to Artios Pharma’s Chief Executive […]

16 November 2017
Read more
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

15 September 2017
Read more
Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Cambridge, UK, 4 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces the appointment of Dr Graeme Smith as its Chief Scientific Officer (CSO). 

4 September 2017
Read more
Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

Cambridge, UK, 12 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA nucleases involved in the DDR.

12 June 2017
Read more
Artios announces formation of world-leading Scientific Advisory Board

Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr […]

8 June 2017
Read more
Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Artios Pharma Ltd (“Artios” or “the Company”) Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy  Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team […]

2 November 2016
Read more
Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

Artios Pharma Ltd (“Artios” or “the Company”) $33.2 Million Series A Financing from SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline Cambridge, UK, 21 September 2016. Artios Pharma Ltd., a new private company focussed […]

21 September 2016
Read more